{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:21Z","timestamp":1793155761039,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005042","name":"Cliniques universitaires Saint-Luc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.dsx.2023.102899","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T10:53:55Z","timestamp":1698922435000},"page":"102899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Advances in cystic fibrosis-related diabetes: Current status and future directions"],"prefix":"10.1016","volume":"17","author":[{"given":"F.","family":"Lurquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buysschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Preumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dsx.2023.102899_bib1","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.dsx.2023.102899_bib2","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2023.102899_bib3","series-title":"Annual data report bethesda, Maryland \u00a92022 cystic fibrosis foundationle","year":"2021"},{"issue":"3","key":"10.1016\/j.dsx.2023.102899_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.dsx.2023.102899_bib5","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.dsx.2023.102899_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.dsx.2023.102899_bib8","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc10-0613","article-title":"Impaired fasting glucose in cystic fibrosis","volume":"33","author":"Frohnert","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2007.05.012","article-title":"Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and No prior history of diabetes","volume":"151","author":"Elder","year":"2007","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2013.06.001","article-title":"Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test","volume":"13","author":"Schmid","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"Supplement_1","key":"10.1016\/j.dsx.2023.102899_bib11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.dsx.2023.102899_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"<scp>ISPAD<\/scp> Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis\u2010related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.dsx.2023.102899_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.dsx.2023.102899_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis\u2013related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.dsx.2023.102899_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI insight"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.dsx.2023.102899_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.14121","article-title":"Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis\u2010related diabetes","volume":"36","author":"Frost","year":"2019","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102899_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2310\/JIM.0b013e3181671788","article-title":"Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes","volume":"56","author":"Hardin","year":"2008","journal-title":"J Invest Med"},{"key":"10.1016\/j.dsx.2023.102899_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630654","article-title":"CFTR deficiency affects glucose homeostasis via regulating GLUT4 plasma membrane transportation","volume":"9","author":"Gu","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.1016\/j.dsx.2023.102899_bib21","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1210\/en.2017-00282","article-title":"Glucose-sensitive CFTR suppresses glucagon secretion by potentiating KATP channels in pancreatic islet \u03b1 cells","volume":"158","author":"Huang","year":"2017","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.dsx.2023.102899_bib22","doi-asserted-by":"crossref","first-page":"e3901","DOI":"10.1210\/clinem\/dgab384","article-title":"Combined indeterminate and impaired glucose tolerance is a novel group at high risk of cystic fibrosis-related diabetes","volume":"106","author":"Potter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00125-021-05423-5","article-title":"Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis","volume":"64","author":"Bonhoure","year":"2021","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib24","doi-asserted-by":"crossref","first-page":"e1793","DOI":"10.1210\/clinem\/dgaa932","article-title":"Glucose tolerance stages in cystic fibrosis are identified by a unique pattern of defects of beta-cell function","volume":"106","author":"Piona","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101455","article-title":"A glycosylated hemoglobin A1c above 6% (42 mmol\/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis","volume":"49","author":"Potter","year":"2023","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.dsx.2023.102899_bib26","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc08-0466","article-title":"Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults","volume":"31","author":"Adler","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102899_bib27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/dc06-1915","article-title":"Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene \u0394F508 mutation","volume":"30","author":"Preumont","year":"2007","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.dsx.2023.102899_bib28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.dsx.2023.102899_bib29","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102899_bib30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcjd.2016.08.221","article-title":"Screening for cystic fibrosis-related diabetes: matching pathophysiology and addressing current challenges","volume":"40","author":"Boudreau","year":"2016","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2023.102899_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jcjd.2018.11.005","article-title":"Validation of a stepwise approach using glycated hemoglobin levels to reduce the number of required oral glucose tolerance tests to screen for cystic fibrosis\u2013related diabetes in adults","volume":"43","author":"Boudreau","year":"2019","journal-title":"Can J Diabetes"},{"issue":"8","key":"10.1016\/j.dsx.2023.102899_bib33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic fibrosis\u2012related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","volume":"45","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.dsx.2023.102899_bib36","series-title":"D\u00e9pistage des anomalies de la tol\u00e9rance au glucose et du diab\u00e8te de mucoviscidose. Position de la Soci\u00e9t\u00e9 fran\u00e7aise de la mucoviscidose (SFM), de la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD) et de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie et diab\u00e9tologie p\u00e9diatriq","author":"Weiss","year":"2023"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib37","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis","volume":"107","author":"Scully","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.dsx.2023.102899_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-2008-1062723","article-title":"Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance","volume":"40","author":"Moreau","year":"2008","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2021.05.010","article-title":"HOMA indices as screening tests for cystic fibrosis-related diabetes","volume":"21","author":"Toin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jpem-2016-0184","article-title":"Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?","volume":"30","author":"Mainguy","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2023.102899_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpeds.2007.09.025","article-title":"Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis","volume":"152","author":"Bismuth","year":"2008","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.dsx.2023.102899_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00592-015-0791-3","article-title":"The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis","volume":"53","author":"Coriati","year":"2016","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2023.102899_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0954-6111(98)90390-0","article-title":"Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes","volume":"92","author":"Yung","year":"1998","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2014.07.014","article-title":"Retinal screening of patients with cystic fibrosis-related diabetes in Wales -- a real eye opener","volume":"14","author":"Roberts","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.dsx.2023.102899_bib48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dmrr.2429","article-title":"Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults","volume":"29","author":"Konrad","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102899_bib50","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib51","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcf.2018.05.005","article-title":"Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes","volume":"17","author":"Frost","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2021.11.011","article-title":"Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies","volume":"21","author":"Caterini","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.dsx.2023.102899_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation - the Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.dsx.2023.102899_bib56","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.dsx.2023.102899_bib57","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor\u2013ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.dsx.2023.102899_bib59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"14","key":"10.1016\/j.dsx.2023.102899_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dsx.2023.102899_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.dsx.2023.102899_bib63","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.dsx.2023.102899_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.dsx.2023.102899_bib65","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.dsx.2023.102899_bib66","series-title":"IDF diabetes atlas","year":"2021"},{"key":"10.1016\/j.dsx.2023.102899_bib67","unstructured":"ECFSPR annual report 2021, Zolin A, Orenti A, Jung A, van Rens J et al, 2023.."},{"issue":"9","key":"10.1016\/j.dsx.2023.102899_bib68","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00125-009-1436-2","article-title":"A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis","volume":"52","author":"Blackman","year":"2009","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib69","first-page":"A19","article-title":"Family history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999-2002","volume":"2","author":"Annis","year":"2005","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib70","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2337\/dc12-0445","article-title":"Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children","volume":"36","author":"Parkkola","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.dsx.2023.102899_bib71","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc06-0654","article-title":"Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications","volume":"29","author":"Andersen","year":"2006","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2023.102899_bib72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ppul.23237","article-title":"Elevation of one hour plasma glucose during oral glucose tolerance testing","volume":"50","author":"Sheikh","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.dsx.2023.102899_bib73","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.dsx.2023.102899_bib75","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2337\/dc06-1576","article-title":"Microvascular complications in cystic fibrosis-related diabetes","volume":"30","author":"Schwarzenberg","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2008.05.008","article-title":"Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD)","volume":"7","author":"van den Berg","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.dsx.2023.102899_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820966428","article-title":"Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes","volume":"11","author":"Kempegowda","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.dsx.2023.102899_bib78","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102899_bib79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.dsx.2023.102899_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.dsx.2023.102899_bib81","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.dsx.2023.102899_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:25:05Z","timestamp":1761729905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":82,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1871402123001959"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102899","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in cystic fibrosis-related diabetes: Current status and future directions","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC).","name":"copyright","label":"Copyright"}],"article-number":"102899"}}